Tissue Factor Inhibitors
1 drugsAbout Tissue Factor
Tissue Factor (TF), or coagulation factor III, is a transmembrane protein initiating blood coagulation upon vascular injury. While essential for hemostasis, aberrant TF expression is implicated in disease, particularly in oncology.
Tissue Factor is a compelling oncology target due to its role in tumor angiogenesis and metastasis. Currently, there is no genetic evidence data available linking Tissue Factor to specific diseases.
Tissue Factor is targeted by one FDA-approved drug, TIVDAK, an antibody-drug conjugate (ADC). SEAGEN is the sole company with an approved drug for this target in oncology.
Top Tissue Factor Drugs
SEAGEN is the only company with an approved Tissue Factor-targeting drug.
The market is highly concentrated, indicating potential entry barriers or limited investment in this target.
Tissue Factor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Tissue Factor, using adc modality.
The lack of modality diversity suggests an opportunity for novel therapeutic approaches beyond ADCs.
Tissue Factor Clinical Trials 11 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Tissue Factor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 2 | 1 | 0 | 67% |
| Phase 2 | 5 | 3 | 0 | 2 | 100% |
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Tissue Factor Drug Approval Timeline (2021 - 2021)
The first and most recent drug approval for Tissue Factor was TIVDAK in 2021.
Recent entry suggests renewed interest, but single approval indicates potential saturation or high development hurdles.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Tissue Factor. A trial counts if an approved drug acting on Tissue Factor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.